Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial

Authors :: Rouphael, Nadine G.
Branche, Angela R.
Diemert, David J.
Falsey, Ann R.
Losada, Cecilia
Baden, Lindsey R.
Frey, Sharon E.
Whitaker, Jennifer A.
Little, Susan J.
Kamidani, Satoshi
Walter, Emmanuel B.
Novak, Richard M.
Rupp, Richard
Jackson, Lisa A.
Babu, Tara M.
Kottkamp, Angelica C.
Luetkemeyer, Anne F.
Immergluck, Lilly C.
Presti, Rachel M.
Bäcker, Martín
Winokur, Patricia L.
Mahgoub, Siham M.
Goepfert, Paul A.
Fusco, Dahlene N.
Atmar, Robert L.
Posavad, Christine M.
Netzl, Antonia
Smith, Derek J.
Telu, Kalyani
Mu, Jinjian
Makowski, Mat
Makhene, Mamodikoe K.
Crandon, Sonja
Montefiori, David C.
Roberts, Paul C.
Beigel, John H.
Source :: medRxiv
Publication Year :: 2023
Publisher :: Cold Spring Harbor Laboratory, 2023.
Abstract: In this brief report, we compare the magnitude and durability of the serologic response of one versus two doses (separated by 56 days) of a variant vaccine (Moderna mRNA-1273 Beta/Omicron BA.1 bivalent vaccine) in adults.

Tools